Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Gorman

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Lancet. Microbe|January 30, 2025
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trialMeagan E Deming, Elizabeth R Brown, Monica A McArthur, et al.
The New England Journal of Medicine|February 10, 2021
Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV InfectionKimberly Page, Michael T Melia, Rebecca T Veenhuis, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Lancet. Microbe|January 30, 2025
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trialMeagan E Deming, Elizabeth R Brown, Monica A McArthur, et al.
The New England Journal of Medicine|February 10, 2021
Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV InfectionKimberly Page, Michael T Melia, Rebecca T Veenhuis, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Pageof 3